EMCURE

Emcure Pharmaceuticals Share Price

₹1,375.90 +7.6 (0.56%)

13 Jun, 2025 02:45

SIP TrendupStart SIP in EMCURE

Start SIP

Performance

  • Low
  • ₹1,352
  • High
  • ₹1,430
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,580
  • Open Price₹1,395
  • Previous Close₹1,368
  • Volume202,312

Investment Returns

  • Over 1 Month + 36.55%
  • Over 3 Month + 45.52%
  • Over 6 Month + 0.54%
  • Over 1 Year + 36.5%
SIP Lightning

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 38.3
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 26,071
  • P/B Ratio
  • 6.3
  • Average True Range
  • 52.46
  • EPS
  • 36.34
  • Dividend Yield
  • 0
  • MACD Signal
  • 74.13
  • RSI
  • 71.97
  • MFI
  • 75.58

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,375.90
+ 7.6 (0.56%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,280.19
  • 50 Day
  • ₹1,184.14
  • 100 Day
  • ₹1,170.71
  • 200 Day
  • ₹1,260.40

Resistance and Support

1385.97 Pivot Speed
  • R3 1,497.93
  • R2 1,463.97
  • R1 1,419.93
  • S1 1,341.93
  • S2 1,307.97
  • S3 1,263.93

What's your outlook on Emcure Pharmaceuticals?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 7,896.00 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 22% and 8% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 65 indicates it belongs to a poor industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-22 Audited Results & Final Dividend
2025-02-06 Quarterly Results
2024-11-07 Quarterly Results
2024-08-13 Quarterly Results

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.92%
2.73%
0.19%
3.06%
5.51%
10.59%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,375 As on 13 June, 2025 | 02:31

The Market Cap of Emcure Pharmaceuticals is ₹26071 Cr As on 13 June, 2025 | 02:31

The P/E ratio of Emcure Pharmaceuticals is 38.3 As on 13 June, 2025 | 02:31

The PB ratio of Emcure Pharmaceuticals is 6.3 As on 13 June, 2025 | 02:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23